Tezspire: Data from P3 WAYPOINT trial (NCT04851964) for chronic rhinosinusitis with nasal polyps in H2 2024 (AstraZeneca) - Jul 25, 2024 - Q2 2024 Results: Data from P3 CROSSING trial (NCT05583227) for eosinophilic esophagitis post 2025
P3 data • Chronic Rhinosinusitis With Nasal Polyps • Eosinophilic Esophagitis • Immunology
|